SCHEMBL5042702

SCHEMBL5042702

COC(=O)C(OC)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.62
HTT P42858 4/20 0.49
LMNA P02545 2/20 0.49
KMT2A Q03164 5/20 0.49
MEN1 O00255 4/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
HPGD P15428 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.47
ACP3 P15309 1/20 0.47
TSHR P16473 1/20 0.46
MAPT P10636 2/20 0.45
DDX3X O00571 1/20 0.45
POLB P06746 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
ATM Q13315 1/20 0.45
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2191046 0.87 ALDH1A1 (0.55) ALDH1A1HTTLMNAKMT2AMEN1
SCHEMBL5037830 0.87 ALDH1A1 (0.64) ALDH1A1HTTLMNAKMT2AMEN1
SCHEMBL8666394 0.87 ALDH1A1 (0.64) ALDH1A1HTTLMNAKMT2AMEN1
SCHEMBL8669891 0.87 ALDH1A1 (0.64) ALDH1A1HTTLMNAKMT2AMEN1
SCHEMBL6676859 0.85 ALDH1A1 (0.59) ALDH1A1HTTLMNAKMT2AMEN1
SCHEMBL2353731 0.84 ALDH1A1 (0.53) ALDH1A1HTTLMNAKMT2AMEN1
SCHEMBL2878642 0.84 PTGS1 (0.55) ALDH1A1HTTLMNAKMT2AMEN1
SCHEMBL15054365 0.82 ALDH1A1 (0.52) ALDH1A1HTTLMNAKMT2AMEN1
SCHEMBL27515178 0.82 ALDH1A1 (0.52) ALDH1A1HTTLMNAKMT2AMEN1
SCHEMBL15229336 0.82 ALDH1A1 (0.52) ALDH1A1HTTLMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed
US-5382590-A Gastrointestinal disorders and nervous system disorders RHONE-POULENC RORER S.A. (FR) 1995-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 ALDH1A1 519/4885HTT 4688/4885LMNA 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.